ACRS

ACRS R&D Expense Growth

56.75%Fiscal year

Period ending:

ACRS FY R&D Growth (YoY)%
ACRS FY R&D Growth (YoY)159.92%-90.05%
2013-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods. Dates are period ends; a fiscal year may differ from a calendar year. Growth compares with the corresponding period one year earlier.

ACRS r&d expense growth history

Year-over-year research & development expense growth. The available annual fiscal periods series contains 13 observations from Dec 31, 2013 to Dec 31, 2025.

Aclaris Therapeutics Inc R&D Expense Growth — Annual fiscal periods
Period endingR&D Expense Growth
56.7469%
-65.8623%
26.4365%
77.6025%
49.3387%
-54.7944%
2.9996%
58.3539%
18.8613%
118.2411%
135.7308%
86.5539%
0%

Compare r&d expense growth

All ACRS financial metrics · ACRS stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.